Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Protocol for a European Delphi study

To develop a European shared decision support tool (SDST), a Delphi process will be used to reach consensus about aspects relating to the continuation or deprescribing of antithrombotic therapy (ATT) in cancer patients at the end of life. As part of the SERENITY project, this study corresponds to work package (WP) 4. Findings from SERENITY WPs 1-3 (realist review, flash mob research, epidemiological and qualitative studies) informed the Delphi study. The WP4 steering committee had two objectives. (1) to build a representative expert panel comprising physicians, pharmacists, nurses and psychologists from eight European countries; and (2) to advise on the content of the Delphi form, divided into four sections: context, content, SDST design and trial outcomes. The form was reviewed by the SERENITY patient and public involvement group to ensure that it met patients’ needs. The Delphi study will take place in three rounds held at 6-week intervals, involving experts from eight countries. Consensus will be reached on items with at least 70% agreement. The steering committee will review and validate the results across the different rounds. Through this Delphi study, the following aspects will be defined: characterisation of candidate patients for discussion about ATT deprescribing; healthcare team roles in ATT decision-making; specific information and communication requirements for patients when making deprescribing decisions; SDST content priorities; and optimal outcomes for the planned clinical trial. This study will feed directly into the development and evaluation of the SDST, aimed at reducing complications and improving quality-of-life in end-of-life cancer patients receiving ATT. • SERENITY project develops a decision support tool for end-of-life cancer patients. • European experts advise about antithrombotic deprescribing in end-of-life cancer care. • A Delphi process will build consensus about the priorities for the support tool.

Authors

Institutions

Publication Details

Journal
Thrombosis Update
Published
2025-05-06
DOI
https://doi.org/10.1016/j.tru.2025.100209
Citations
2
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
6.26

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Protocol for a European Delphi study

Imène Deneche, Camille Couffignal, Sebastian Szmit, Laurent Bertoletti et al.
2 citations
Thrombosis Update
Health Systems, Economic Evaluations, Quality of Life
6.26
article

Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Protocol for a European Delphi study

Imène Deneche, Camille Couffignal, Sebastian Szmit, Laurent Bertoletti, Jacobijn Gussekloo, Rashmi Kumar, Isabelle Mahé, Suzanne C. Cannegieter, Alessandra Gava, Marieke J. H. A. Kruip, Mark Pearson, Anette Arbjerg Højen, Adrian Edwards, Stavros Konstantinides, Frederikus Albertus Klok, Johanneke E. A. Portielje, Kate Lifford, Kathy Seddon, Simon Noble, Denise Abbel, Miriam J. Johnson, Carme Font, Eric Ligtenberg, N. Mohammed, Stella Trompet, Luigi Maiorana, Simon P. Mooijaart, Johan Langendoen
article en
2 citations

Abstract

To develop a European shared decision support tool (SDST), a Delphi process will be used to reach consensus about aspects relating to the continuation or deprescribing of antithrombotic therapy (ATT) in cancer patients at the end of life. As part of the SERENITY project, this study corresponds to work package (WP) 4. Findings from SERENITY WPs 1-3 (realist review, flash mob research, epidemiological and qualitative studies) informed the Delphi study. The WP4 steering committee had two objectives. (1) to build a representative expert panel comprising physicians, pharmacists, nurses and psychologists from eight European countries; and (2) to advise on the content of the Delphi form, divided into four sections: context, content, SDST design and trial outcomes. The form was reviewed by the SERENITY patient and public involvement group to ensure that it met patients’ needs. The Delphi study will take place in three rounds held at 6-week intervals, involving experts from eight countries. Consensus will be reached on items with at least 70% agreement. The steering committee will review and validate the results across the different rounds. Through this Delphi study, the following aspects will be defined: characterisation of candidate patients for discussion about ATT deprescribing; healthcare team roles in ATT decision-making; specific information and communication requirements for patients when making deprescribing decisions; SDST content priorities; and optimal outcomes for the planned clinical trial. This study will feed directly into the development and evaluation of the SDST, aimed at reducing complications and improving quality-of-life in end-of-life cancer patients receiving ATT. • SERENITY project develops a decision support tool for end-of-life cancer patients. • European experts advise about antithrombotic deprescribing in end-of-life cancer care. • A Delphi process will build consensus about the priorities for the support tool.

Thrombosis UpdateVol. 19
Inserm (FR), University of Hull (GB), Johannes Gutenberg University Mainz (DE), Aalborg University Hospital (DK), Leiden University Medical Center (NL), Codarts Rotterdam (NL), Erasmus MC (NL), Mines Saint-Étienne (FR), University Medical Center of the Johannes Gutenberg University Mainz (DE), University of Ragusa (IT), Assistance Publique – Hôpitaux de Paris (FR), Hospital Clínic de Barcelona (ES), Postgraduate School of Molecular Medicine (PL), Hôpital Bichat-Claude-Bernard (FR), Hull York Medical School (GB), Cardiff University (GB), Cardiff Metropolitan University (GB), Université Jean Monnet (FR), Aalborg University (DK)
HORIZON EUROPE Framework Programme
Peace, Justice and strong institutions
Openalex Percentile: Top 4%
Health Systems, Economic Evaluations, Quality of Life
6.26
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.